<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="Activity\PMC7662555\results\search\disease\results.xml">
  <result pre="(CAR-T) are considered novel biological agents, designed to selectively attack" exact="cancer" post="cells expressing specific antigens, with demonstrated clinical activity in"/>
  <result pre="the required facilities and regulatory landscape in the context of" exact="cancer" post="centers. CAR-T cells CAR-T process CAR-T Unit CAR-T Specialist"/>
  <result pre="cells infiltrating the tumor lesions (3â€&quot;10). The crescent knowledge of" exact="cancer" post="immunology and immunotherapy has allowed the development of novel"/>
  <result pre="paradigm that patientâ€™s immune system represents effective â€œliving drugsâ€� against" exact="cancer" post="cells. Among these, adoptive cell therapy (ACT) that implies"/>
  <result pre="has shown promising clinical activity improving the overall survival of" exact="cancer" post="patients (12). T-lymphocytes engineered with Chimeric Antigen Receptors (CARs),"/>
  <result pre="trials showed durable clinical responses in both adult and pediatric" exact="cancer" post="patients with disease relapse or refractory to other therapeutic"/>
  <result pre="of overall survival (OS) were documented in patients with either" exact="acute lymphoblastic leukemia" post="(ALL) (21, 22) or high grade non-Hodgkin lymphomas (NHLs),"/>
  <result pre="overall survival (OS) were documented in patients with either acute" exact="lymphoblastic leukemia" post="(ALL) (21, 22) or high grade non-Hodgkin lymphomas (NHLs),"/>
  <result pre="survival (OS) were documented in patients with either acute lymphoblastic" exact="leukemia" post="(ALL) (21, 22) or high grade non-Hodgkin lymphomas (NHLs),"/>
  <result pre="or high grade non-Hodgkin lymphomas (NHLs), including diffuse large B-cell" exact="lymphoma" post="(DLBCL) (23, 24) and mantle cell lymphoma (ML) (25)."/>
  <result pre="(NHLs), including diffuse large B-cell lymphoma (DLBCL) (23, 24) and" exact="mantle cell lymphoma" post="(ML) (25). These clinical trials led to the accelerated"/>
  <result pre="diffuse large B-cell lymphoma (DLBCL) (23, 24) and mantle cell" exact="lymphoma" post="(ML) (25). These clinical trials led to the accelerated"/>
  <result pre="cell therapy for B-cell malignancies involve neurotoxicity, B-cell aplasia and" exact="hypogammaglobulinemia" post="(26). CAR-T cells have been also investigated for the"/>
  <result pre="drugs against solid tumors and the optimal clinical setting for" exact="cancer" post="patients (28, 29, 35). The organizational and regulatory aspects"/>
  <result pre="environment; ii) high proliferation capacity, even after multiple encountering with" exact="cancer" post="cells; iii) long-term persistence; iiii) absence or low degree"/>
  <result pre="allow promotion of a universal cytokine-mediated activation, targeting even those" exact="cancer" post="cells that would be invisible to CAR-T cells. Notably,"/>
  <result pre="experienced multi-disciplinary teams working together to care for intensively treated" exact="cancer" post="patients are mandatory. Nevertheless, regulatory and logistic landscape of"/>
  <result pre="no longer detectable. â€œBridgeâ€� chemotherapy plays an important role in" exact="acute lymphoblastic leukemia" post="(ALL) as leukemic blast burden at the time of"/>
  <result pre="longer detectable. â€œBridgeâ€� chemotherapy plays an important role in acute" exact="lymphoblastic leukemia" post="(ALL) as leukemic blast burden at the time of"/>
  <result pre="detectable. â€œBridgeâ€� chemotherapy plays an important role in acute lymphoblastic" exact="leukemia" post="(ALL) as leukemic blast burden at the time of"/>
  <result pre="involved sites are additional factors to be considered also in" exact="lymphoma" post="patients: many regimens are indicated in this phase, and"/>
  <result pre="and 28% of adult patients with diffuse large B cell" exact="lymphoma" post="(DLBCL) in the JULIET trial (52), while the ZUMA-1"/>
  <result pre="activation syndrome and CRS, B-cell aplasia, hypogammaglobulinemia. Neutropenia, thrombocytopenia, and" exact="anemia" post="are commonly observed in CAR-T cell treated patients, but"/>
  <result pre="make such living drugs available to a broad number of" exact="cancer" post="patients. Author Contributions All authors contributed to the article"/>
  <result pre="Â 10.1016/j.coi.2013.03.004 6BindeaGMlecnikBAngellHKGalonJThe immune landscape of human tumors: Implications for" exact="cancer" post="immunotherapy. Oncoimmunology (2014) 3(1):e27456. Â 10.4161/onci.2745624800163 7BindeaGMlecnikBFridmanWHGalonJThe prognostic impact"/>
  <result pre="prognostic impact of anti-cancer immune response: a novel classification of" exact="cancer" post="patients. Semin Immunopathol (2011) 33(4):335â€&quot;40. Â 10.1007/s00281-011-0264-x 8FridmanWHGalonJDieu-NosjeanM-CCremerIFissonSDamotteDet al.Immune"/>
  <result pre="and helper cells (Th1, Th2, Treg, Th17) in patients with" exact="colorectal cancer." post="Cancer Res (2011) 71(4):1263â€&quot;71. Â 10.1158/0008-5472.CAN-10-2907 11TangJShalabiAHubbard-LuceyVMComprehensive analysis of"/>
  <result pre="Insight (2018) 3(1):e96976. Â 10.1172/jci.insight.96976 15JuneCHPrinciples of adoptive T cell" exact="cancer" post="therapy. J Clin Invest (2007) 117(5):1204â€&quot;12. Â 10.1172/JCI31446 16KohnDBDottiGBrentjensRSavoldoBJensenMCooperLet"/>
  <result pre="Mol Ther (2011) 19:432â€&quot;8. Â 10.1038/mt.2011.1 17VonderheideRHJuneCHA translational bridge to" exact="cancer" post="immunotherapy: Exploiting costimulation and target antigens for active and"/>
  <result pre="Â 10.1038/nbt0102-70 20BrentjensRJSantosENikhaminYYehRMatsushitaMLa PerleetKet al.Genetically targeted T cells eradicate systemic" exact="acute lymphoblastic leukemia" post="xenografts. Clin Cancer Res (2007) 13(18):5426â€&quot;35. Â 10.1158/1078-0432.CCR-07-0674 21MaudeSLLaetschTWBuechnerJRivesSBoyerMBittencourtHet"/>
  <result pre="10.1038/nbt0102-70 20BrentjensRJSantosENikhaminYYehRMatsushitaMLa PerleetKet al.Genetically targeted T cells eradicate systemic acute" exact="lymphoblastic leukemia" post="xenografts. Clin Cancer Res (2007) 13(18):5426â€&quot;35. Â 10.1158/1078-0432.CCR-07-0674 21MaudeSLLaetschTWBuechnerJRivesSBoyerMBittencourtHet"/>
  <result pre="20BrentjensRJSantosENikhaminYYehRMatsushitaMLa PerleetKet al.Genetically targeted T cells eradicate systemic acute lymphoblastic" exact="leukemia" post="xenografts. Clin Cancer Res (2007) 13(18):5426â€&quot;35. Â 10.1158/1078-0432.CCR-07-0674 21MaudeSLLaetschTWBuechnerJRivesSBoyerMBittencourtHet"/>
  <result pre="10.1158/1078-0432.CCR-07-0674 21MaudeSLLaetschTWBuechnerJRivesSBoyerMBittencourtHet al.Tisagenlecleucel in children and young adults with B-cell" exact="lymphoblastic leukemia." post="N Engl J Med (2018) 378(5):439â€&quot;48. Â 10.1056/NEJMoa1709866 22ParkJHRiviÃ¨reIGonenMWangXSÃ©nÃ©chalBCurranKJet"/>
  <result pre="Â 10.1056/NEJMoa1709866 22ParkJHRiviÃ¨reIGonenMWangXSÃ©nÃ©chalBCurranKJet al.Long-term follow-up of CD19 CAR therapy in" exact="acute lymphoblastic leukemia." post="N Engl J Med (2018) 378(5):449â€&quot;59. Â 10.1056/NEJMoa1709919 23LockeFLNeelapuSSBartlettNLSiddiqiTChavezJCHosingCMet"/>
  <result pre="10.1056/NEJMoa1709866 22ParkJHRiviÃ¨reIGonenMWangXSÃ©nÃ©chalBCurranKJet al.Long-term follow-up of CD19 CAR therapy in acute" exact="lymphoblastic leukemia." post="N Engl J Med (2018) 378(5):449â€&quot;59. Â 10.1056/NEJMoa1709919 23LockeFLNeelapuSSBartlettNLSiddiqiTChavezJCHosingCMet"/>
  <result pre="safety and activity of axicabtagene ciloleucel in refractory large B-cell" exact="lymphoma" post="(ZUMA-1): a single-arm, multicentre, phase 1â€&quot;2 trial. Lancet Oncol"/>
  <result pre="Mol Sci (2019) 20(23):5942. Â 10.3390/ijms20235942 32LeuciVCasucciGMGrignaniGRotoloRRossottiUVignaEet al.CD44v6 as innovative" exact="sarcoma" post="target for CAR-redirected CIK cells. Oncoimmunology (2018) 7(5):e1423167. Â"/>
  <result pre="10.1080/2162402X.2017.142316729721373 33JindalVAroraEGuptaSLalAMasabMPotdarRProspects of chimeric antigen receptor T cell therapy in" exact="ovarian cancer." post="Med Oncol (2018) 35(5):70. Â 10.1007/s12032-018-1131-629651744 34QuintarelliCOrlandoDBoffaIGuercioMPolitoVAPetrettoAet al.Choice of"/>
  <result pre="36(5):471â€&quot;82. Â 10.1016/j.ccell.2019.09.006 38BeattyGLGladneyWLImmune escape mechanisms as a guide for" exact="cancer" post="immunotherapy. Clin Cancer Res (2015) 21(4):687â€&quot;92. Â 10.1158/1078-0432.CCR-14-1860 39GradaZHegdeMByrdTShafferDGhaziABrawleyVet"/>
  <result pre="10.1158/1078-0432.CCR-14-1860 39GradaZHegdeMByrdTShafferDGhaziABrawleyVet al.TanCAR: A novel bispecific chimeric antigen receptor for" exact="cancer" post="immunotherapy. Mol Ther Nucleic Acids (2013) 2(7):e105. Â 10.1038/mtna.2013.3223839099"/>
  <result pre="der StegenSJParente PereiraAet al.Dual targeting of ErbB2 and MUC1 in" exact="breast cancer" post="using chimeric antigen receptors engineered to provide complementary signaling."/>
  <result pre="StegenSJParente PereiraAet al.Dual targeting of ErbB2 and MUC1 in breast" exact="cancer" post="using chimeric antigen receptors engineered to provide complementary signaling."/>
  <result pre="1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle" exact="cancer" post="can be effectively eradicated by modified Anti-MUC1 chimeric antigen"/>
  <result pre="SousaPBatista-SilvaLRet al.Transposon-mediated generation of CAR-T cells shows efficient anti B-cell" exact="leukemia" post="response after ex vivo expansion. Gene Ther (2020) 27(1-2):85â€&quot;95."/>
  <result pre="Immunol (2005) 26(2):111â€&quot;7. Â 10.1016/j.it.2004.12.003 55KochenderferJNDudleyMEKassimSHSomervilleRCarpenterRStetler-StevensonMet al.Chemotherapy-refractory diffuse large B-cell" exact="lymphoma" post="and indolent B-cell malignancies can be effectively treated with"/>
  <result pre="Clin Oncol (2015) 33(6):540â€&quot;9. Â 10.1200/JCO.2014.56.2025 56TurtleCJHanafiLABergerCHudecekMPenderBRobinsonetEet al.Immunotherapy of non-Hodgkinâ€™s" exact="lymphoma" post="with a defined ratio of CD8+ and CD4+ CD19-specific"/>
  <result pre="25(4):625â€&quot;38. Â 10.1016/j.bbmt.2018.12.758 60MaudeSLTeacheyDTPorterDLGruppSACD19-targeted chimeric antigen receptor T-cell therapy for" exact="acute lymphoblastic leukemia." post="Blood (2015) 125(26):4017â€&quot;23. Â 10.1182/blood-2014-12-580068 61NeelapuSSTummalaSKebriaeiPWierdaWGutierrezCLockeFet al.Chimeric antigen receptor"/>
  <result pre="Â 10.1016/j.bbmt.2018.12.758 60MaudeSLTeacheyDTPorterDLGruppSACD19-targeted chimeric antigen receptor T-cell therapy for acute" exact="lymphoblastic leukemia." post="Blood (2015) 125(26):4017â€&quot;23. Â 10.1182/blood-2014-12-580068 61NeelapuSSTummalaSKebriaeiPWierdaWGutierrezCLockeFet al.Chimeric antigen receptor"/>
  <result pre="management of 19-28z CAR T cell therapy in B cell" exact="acute lymphoblastic leukemia." post="Sci Transl Med (2014) 6(224):224ra25. Â 10.1126/scitranslmed.3008226 65BrentjensRJDavilaMLRiviereIParkJWangXCowellLet al.CD19-targeted"/>
  <result pre="of 19-28z CAR T cell therapy in B cell acute" exact="lymphoblastic leukemia." post="Sci Transl Med (2014) 6(224):224ra25. Â 10.1126/scitranslmed.3008226 65BrentjensRJDavilaMLRiviereIParkJWangXCowellLet al.CD19-targeted"/>
  <result pre="T cells rapidly induce molecular remissions in adults with chemotherapy-refractory" exact="acute lymphoblastic leukemia." post="Sci Transl Med (2013) 5(177):177ra38. Â 10.1126/scitranslmed.3005930 66KochenderferJNDudleyMEFeldmanSAWilsonWHSpanerDMaricIet al.B-cell"/>
  <result pre="cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute" exact="lymphoblastic leukemia." post="Sci Transl Med (2013) 5(177):177ra38. Â 10.1126/scitranslmed.3005930 66KochenderferJNDudleyMEFeldmanSAWilsonWHSpanerDMaricIet al.B-cell"/>
 </snippets>
</snippetsTree>
